Last reviewed · How we verify

Tislelizumab + platinum-based chemotherapy

Fujian Cancer Hospital · FDA-approved active Small molecule

Tislelizumab + platinum-based chemotherapy is a PD-1 inhibitor Small molecule drug developed by Fujian Cancer Hospital. It is currently FDA-approved for Non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy, Squamous cell carcinoma of the head and neck in combination with platinum-based chemotherapy.

Tislelizumab blocks PD-1 on T cells to restore anti-tumor immunity, combined with platinum chemotherapy to enhance cytotoxic effects against cancer cells.

Tislelizumab blocks PD-1 on T cells to restore anti-tumor immunity, combined with platinum chemotherapy to enhance cytotoxic effects against cancer cells. Used for Non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy, Squamous cell carcinoma of the head and neck in combination with platinum-based chemotherapy.

At a glance

Generic nameTislelizumab + platinum-based chemotherapy
SponsorFujian Cancer Hospital
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Tislelizumab is a humanized monoclonal antibody that binds to programmed death receptor-1 (PD-1), preventing interaction with its ligands (PD-L1/PD-L2) and thereby releasing the brake on T-cell-mediated anti-tumor immunity. Platinum-based chemotherapy induces DNA damage and cell death while potentially increasing tumor immunogenicity. The combination leverages both direct cytotoxic chemotherapy and immune checkpoint inhibition for synergistic anti-tumor activity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tislelizumab + platinum-based chemotherapy

What is Tislelizumab + platinum-based chemotherapy?

Tislelizumab + platinum-based chemotherapy is a PD-1 inhibitor drug developed by Fujian Cancer Hospital, indicated for Non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy, Squamous cell carcinoma of the head and neck in combination with platinum-based chemotherapy.

How does Tislelizumab + platinum-based chemotherapy work?

Tislelizumab blocks PD-1 on T cells to restore anti-tumor immunity, combined with platinum chemotherapy to enhance cytotoxic effects against cancer cells.

What is Tislelizumab + platinum-based chemotherapy used for?

Tislelizumab + platinum-based chemotherapy is indicated for Non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy, Squamous cell carcinoma of the head and neck in combination with platinum-based chemotherapy.

Who makes Tislelizumab + platinum-based chemotherapy?

Tislelizumab + platinum-based chemotherapy is developed and marketed by Fujian Cancer Hospital (see full Fujian Cancer Hospital pipeline at /company/fujian-cancer-hospital).

What drug class is Tislelizumab + platinum-based chemotherapy in?

Tislelizumab + platinum-based chemotherapy belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Tislelizumab + platinum-based chemotherapy in?

Tislelizumab + platinum-based chemotherapy is FDA-approved (marketed).

What are the side effects of Tislelizumab + platinum-based chemotherapy?

Common side effects of Tislelizumab + platinum-based chemotherapy include Fatigue, Nausea, Decreased appetite, Immune-related adverse events (pneumonitis, hepatitis, colitis), Anemia, Thrombocytopenia.

What does Tislelizumab + platinum-based chemotherapy target?

Tislelizumab + platinum-based chemotherapy targets PD-1 and is a PD-1 inhibitor.

Related